Assetmark Inc. Decreases Position in Vertex Pharmaceuticals Incorporated $VRTX

Assetmark Inc. lowered its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.8% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 89,850 shares of the pharmaceutical company’s stock after selling 2,541 shares during the period. Assetmark Inc.’s holdings in Vertex Pharmaceuticals were worth $35,189,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Kovack Advisors Inc. raised its holdings in Vertex Pharmaceuticals by 1.9% in the 2nd quarter. Kovack Advisors Inc. now owns 1,280 shares of the pharmaceutical company’s stock valued at $570,000 after acquiring an additional 24 shares during the last quarter. Washington Trust Advisors Inc. increased its stake in shares of Vertex Pharmaceuticals by 8.4% in the 2nd quarter. Washington Trust Advisors Inc. now owns 323 shares of the pharmaceutical company’s stock worth $144,000 after acquiring an additional 25 shares during the last quarter. Signature Wealth Management Group increased its stake in shares of Vertex Pharmaceuticals by 0.6% in the 2nd quarter. Signature Wealth Management Group now owns 4,244 shares of the pharmaceutical company’s stock worth $1,889,000 after acquiring an additional 26 shares during the last quarter. Hohimer Wealth Management LLC boosted its position in shares of Vertex Pharmaceuticals by 1.2% during the 2nd quarter. Hohimer Wealth Management LLC now owns 2,123 shares of the pharmaceutical company’s stock valued at $945,000 after acquiring an additional 26 shares during the last quarter. Finally, Legacy Wealth Asset Management LLC boosted its position in shares of Vertex Pharmaceuticals by 1.8% during the 3rd quarter. Legacy Wealth Asset Management LLC now owns 1,442 shares of the pharmaceutical company’s stock valued at $565,000 after acquiring an additional 26 shares during the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Trading Up 5.7%

Shares of NASDAQ:VRTX opened at $491.47 on Friday. The firm has a 50 day simple moving average of $459.98 and a 200-day simple moving average of $427.76. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $519.68. The company has a market capitalization of $124.70 billion, a PE ratio of 32.06 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.90%. The company had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.18 billion. During the same period last year, the business earned $3.98 earnings per share. The company’s quarterly revenue was up 9.5% on a year-over-year basis. As a group, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals News Roundup

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Revenue and product momentum — Q4 revenue of ~$3.19B (≈+9.5% YoY) came in at or slightly above many forecasts, driven by cystic fibrosis product sales and new launches (Alyftrek, Casgevy, Journavx), supporting near-term cash flow expectations. Article Title
• Positive Sentiment: Analyst upgrade and bullish targets — Oppenheimer upgraded VRTX to “outperform” with a $540 target; several other firms recently raised targets or reiterated buys, which can drive momentum and institutional demand. Article Title
• Positive Sentiment: Pipeline diversification highlighted — Company commentary emphasized growth beyond CF (autoimmune partnerships/expansion), which reduces concentration risk and supports longer-term upside. Article Title
• Neutral Sentiment: 2026 revenue guidance roughly in-line — Management set FY2026 revenue guidance around $13.0–13.1B, largely matching Street expectations; this limits downside from guidance surprises but is not a bullish catalyst on its own. Article Title
• Neutral Sentiment: Full materials available for modeling — The slide deck and earnings call transcript are posted; analysts will parse product trends and margins to update models. Article Title
• Negative Sentiment: Small EPS miss and mixed metric comparisons — EPS was ~$5.03 vs. consensus near $5.05–$5.07; some outlets flagged revenue slightly below certain Street models, triggering near-term profit-taking. Article Title
• Negative Sentiment: Insider selling — Multiple senior executives disclosed open-market sales this week (EVPs, CAO). While common for tax/diversification, the cluster of sales can amplify short-term negative sentiment. Article Title
• Negative Sentiment: After-hours weakness — The EPS miss plus insider sales pressured shares in after-hours trading, reflecting short-term profit-taking before today’s rebound. Article Title

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, EVP Charles F. Wagner, Jr. sold 14,000 shares of the stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $456.00, for a total transaction of $6,384,000.00. Following the completion of the sale, the executive vice president owned 37,725 shares in the company, valued at approximately $17,202,600. This represents a 27.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Mark E. Bunnage sold 2,021 shares of the firm’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total value of $930,529.03. Following the transaction, the executive vice president directly owned 12,914 shares in the company, valued at approximately $5,945,993.02. This represents a 13.53% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 99,352 shares of company stock valued at $45,037,314. 0.20% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have recently commented on VRTX. Scotiabank lifted their price target on shares of Vertex Pharmaceuticals from $495.00 to $558.00 and gave the company an “outperform” rating in a research report on Friday. Leerink Partners boosted their price target on shares of Vertex Pharmaceuticals from $456.00 to $525.00 and gave the stock an “outperform” rating in a research note on Monday, December 29th. Wolfe Research raised shares of Vertex Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $548.00 price target on the stock in a research report on Tuesday, January 6th. Wells Fargo & Company raised their price objective on shares of Vertex Pharmaceuticals from $460.00 to $515.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Finally, Oppenheimer upgraded shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $540.00 price objective for the company in a report on Friday. Twenty-two equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $537.05.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.